We Give Shareholders A Voice.

The market fluctuates, but we don’t. We give you straight answers from real attorneys who have spent decades helping shareholders protect their investments and recover their losses.

Settlements

$9.5 Million

Babcock & Wilcox Enterprises, Inc.

$14 Million

Corcept Therapeutics

$40 Million

U.S. Steel

$7 Million

Aqua Metals, Inc.

$7.025 Million

WideOpenWest, Inc.

$8.25 Million

Helios and Matheson Analytics Inc.

$13.85 Million

Illumina, Inc.

$14.5 Million

Avon Products Inc.

I think you’ve done a superb job and I really appreciate the way this case was handled.

The Honorable Ronald B. Rubin in Teoh v. Ferrantino, C.A. No. 356627 (Cir. Ct. for Montgomery Cnty., MD 2012)

…a model for how [the] great legal profession should conduct itself.

Justice Timothy S. Driscoll in Grossman v. State Bancorp, Inc., Index No. 600469/2011 (N.Y. Sup. Ct. Nassau Cnty. Nov. 29, 2011)

I find the firm to be well-qualified to serve as Lead Counsel.

The Honorable Andrew L. Carter, Jr. In Snyder v. Baozun Inc., No. 1:19-CV-11290 (S.D.N.Y. Sept. 8, 2020)

In appointing the Firm Lead Counsel, the Honorable Analisa Torres noted our “extensive experience” in securities litigation.

White Pine Invs. v. CVR Ref., LP, No. 20 CIV. 2863 (S.D.N.Y. Jan. 5, 2021)

Class Counsel have demonstrated that they are skilled in this area of the law and therefore adequate to represent the Settlement Class as well.

Furthermore, with the increasing importance of compliance and risk management, kyc for law firms has become an essential component of legal services.

The Honorable Barry Ted Moskowitz in In re Regulus Therapeutics Inc. Sec. Litig., No. 3:17-CV-182-BTM-RBB (S.D. Cal. Oct. 30, 2020)

Who We Are

1
1
1
1
1
1

We're here for you

Find an Attorney

Required Field

Coin Image

Don't hesitate

Find a Case

Upcoming Deadlines

Investors interested in taking an active role in litigation have a limited time to petition the court for appointment as lead plaintiff. If you are interested in acting as a lead plaintiff, submit your transactions before the deadline, and our analysts will calculate your losses. Don't wait till the last minute- discuss your options today.
View All Deadlines

Due

Today

AAP

Advance Auto Parts, Inc.

Deadline

December 8 2023

Class Period

11/16/22 - 5/30/23

Allegations

The complaint alleges that defendants made false and/or materially misleading statements that: 1) misrepresented the efficacy of AAP’s strategic pricing initiative and the impact of price reductions; 2) omitted and/or concealed the negative impacts of the pricing initiative; 3) provided investors with an overly optimistic perception of AAP’s operations; and 4) created the false impression that inflation and macroeconomic factors had an insubstantial impact on the Company’s margins. On May 31, 2023, AAP held its quarterly earnings call for 2023 first quarter. During that call, President and CEO Thomas R. Greco (“Greco”) conceded, “our financial results in the first quarter were well below expectations.” Because the Company slashed prices on products, Greco stated “we had less price realization than plans, which put substantially higher pressure on our product margin price.” Executive Vice President and Chief Financial Officer, Jeffrey W. Shepherd revealed during the May call that the Company’s strategic pricing program resulted in the Company being “unable to price to cover product costs in the quarter.” The Company consequently revised downward its 2023 guidance to an operating margin of 5% to 5.3% from the previously announced 7.8% to 9.2% margins. Following this news, the Company’s stock price fell by $39.31 per share, from $112.20 per share to $72.89 per share on May 31, 2023.

Class Period

11/16/22 - 5/30/23

Deadline

December 8 2023

Learn More

Due

Today

KVUE

Kenvue Inc.

Deadline

December 8 2023

Class Period

This lawsuit is on behalf of persons who purchased or otherwise acquired Kenvue securities pursuant and/or traceable to the registration statement and related prospectus issued in connection with Kenvue’s May 2023 initial public offering.

Allegations

(1) Kenvue faces potential headwinds as a result of confirmed concerns about the efficacy of phenylephrine, which it knew or should have known; (2) Kenvue did not discuss risks relating to the efficacy of phenylephrine (or “PE”) in its IPO, the utility of which had been questioned since at least 2007; (3) while the Company disclosed risks relating to litigation, it did not disclose specific risk relating to potential litigation arising from adverse findings on the efficacy of phenylephrine; and (4) as a result, defendants’ public statements were materially false and misleading at all relevant times and negligently prepared.

Class Period

This lawsuit is on behalf of persons who purchased or otherwise acquired Kenvue securities pursuant and/or traceable to the registration statement and related prospectus issued in connection with Kenvue’s May 2023 initial public offering.

Deadline

December 8 2023

Learn More

4

Days Left

NKLA

Nikola Corporation

Deadline

December 12 2023

Class Period

2/24/22 - 9/7/23

Allegations

(i) the Company maintained deficient safety and structural controls related to its manufacturing of battery components; (ii) the foregoing deficiencies rendered Nikola’s vehicles unsafe to operate and thus unusable, thereby raising the likelihood of a product recall; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times.

Class Period

2/24/22 - 9/7/23

Deadline

December 12 2023

Learn More

7

Days Left

DMTK

DermTech, Inc.

Deadline

December 15 2023

Class Period

3/8/21 - 11/3/22

Allegations

(1) the Company experienced challenges with collections from commercial payors; (2) as a result, there was a lower average selling price for the DermTech Melanoma Test; (3) as a result of the foregoing, the Company’s revenue growth would be adversely impacted; and (4) as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Class Period

3/8/21 - 11/3/22

Deadline

December 15 2023

Learn More

11

Days Left

FTCH

Farfetch Limited

Deadline

December 19 2023

Class Period

3/9/23 - 8/17/23

Allegations

(i) Farfetch was experiencing a significant slowdown in growth in the U.S. and China; (ii) Farfetch also faced onboarding challenges impacting the launch of its Reebok partnership; (iii) Farfetch downplayed challenges it faced with respect to, and/or overstated its ability to manage, its supply chain and inventory; (iv) all the foregoing was having a significant negative impact on Farfetch’s revenue and gross merchandise value growth; (v) accordingly, Farfetch was unlikely to meet market expectations for its Q2 2023 financial results or its own FY 2023 revenue guidance; and (vi) as a result, the Company’s public statements were materially false and misleading at all relevant times.

Class Period

3/9/23 - 8/17/23

Deadline

December 19 2023

Learn More

11

Days Left

ADBE

Adobe Inc.

Deadline

December 19 2023

Class Period

7/23/21 - 9/15/22

Allegations

(a) Figma was growing its market share and was becoming a leader in user experience design; (b) Figma was in direct competition with Adobe on user experience design; (c) Adobe’s product “Express” was not an effective counter to Figma’s growing market share in bringing new customers to Adobe’s paid offerings; (d) Adobe’s other offerings were not succeeding in competing with Figma on user experience design; and (e) Adobe was losing market share to Figma.

Class Period

7/23/21 - 9/15/22

Deadline

December 19 2023

Learn More

18

Days Left

DCGO

DocGo Inc.

Deadline

December 26 2023

Class Period

11/8/22 - 9/17/23

Allegations

(i) DocGo’s executive hiring processes were inadequate to fully review and vet the professional and academic backgrounds of job candidates; (ii) the foregoing increased the likelihood of disruptive executive turnover; (iii) contrary to its representations to investors, DocGo had overstated the efficacy of its mobile health and medical transportation services, the very services contemplated by the relocation contract between the Company and New York City; (iv) all of the foregoing, once revealed, was likely to subject DocGo to significant reputational and/or regulatory scrutiny that would negatively impact the Company’s financial position and/or prospects; and (v) as a result, the Company’s public statements were materially false and misleading at all relevant times.

Class Period

11/8/22 - 9/17/23

Deadline

December 26 2023

Learn More

25

Days Left

SEDG

SolarEdge Technologies, Inc.

Deadline

January 2 2024

Class Period

5/3/23 - 10/19/23

Allegations

(1) the Company’s distribution channels in Europe had higher than optimal inventory levels; (2) as a result, the Company was experiencing substantial cancellations and pushouts of existing backlog from its European distributors; (3) as a result, the Company’s backlog and guidance was overstated; and (4) as a result, defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Class Period

5/3/23 - 10/19/23

Deadline

January 2 2024

Learn More

25

Days Left

OTLK

Outlook Therapeutics, Inc.

Deadline

January 2 2024

Class Period

12/29/22 - 8/29/23

Allegations

(i) there was a lack of substantial evidence supporting the Company's lead product candidate, ONS-5010, as a treatment for wet age-related macular degeneration; (ii) Outlook and/or its manufacturing partner had deficient chemistry manufacturing and controls and other manufacturing issues for ONS-5010, which remained unresolved at the time the ONS-5010 biologics license application (“BLA”) was resubmitted to the U.S. Food and Drug Administration ("FDA"); (iii) as a result of all the foregoing, the FDA was unlikely to approve the ONS-5010 BLA in its present form; (iv) accordingly, ONS-5010’s regulatory and commercial prospects were overstated; and (v) as a result, the Company’s public statements were materially false and misleading at all relevant times.

Class Period

12/29/22 - 8/29/23

Deadline

January 2 2024

Learn More

25

Days Left

BCLI

Brainstorm Cell Therapeutics Inc.

Deadline

January 2 2024

Class Period

8/15/22 - 9/27/23

Allegations

(1) Brainstorm Cell downplayed the severity of the refusal to file letter it received from the U.S. Food and Drug Administration regarding NurOwn ; (2) Brainstorm Cell continued to conceal the risks associated with the submission of the Biologics License Application for NurOwn; and (3) as a result, defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Class Period

8/15/22 - 9/27/23

Deadline

January 2 2024

Learn More

25

Days Left

BCS

Barclays PLC

Deadline

January 2 2024

Class Period

7/22/19 - 10/12/23

Allegations

(1) contrary to his false public assertions, Barclays' CEO, Jes Staley, had a close relationship with Jeffrey Epstein; (2) Staley was reportedly aware of Jeffrey Epstein’s criminal activities and may have even sexually assaulted a victim who had previously been trafficked by Jeffrey Epstein; (3) Staley’s close, personal relationship with Jeffrey Epstein and potential criminal activity could, if discovered, bring reputational, legal, and financial harm to Barclays; (4) as a result, Barclays response to the British Financial Conduct Authority'("FCA") inquiry regarding Staley’s relationship with Epstein was materially false; (5) Barclays, having become aware of information contradicting its response to the FCA’s inquiry, then failed to update the response so that it would be accurate, or otherwise take any meaningful action; and (6) as a result, defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all times.

Class Period

7/22/19 - 10/12/23

Deadline

January 2 2024

Learn More

28

Days Left

HLLY

Holley Inc.

Deadline

January 5 2024

Class Period

7/21/21 - 2/6/23

Allegations

i) as a result of Holley’s extensive focus on its direct-to-consumer (“DTC”) channel, Holley’s critically important relationships with its resellers and distributors, whose business made up the vast majority of Holley’s revenue, were suffering significant damage; (ii) Holley used discounting and other similar efforts to grow its DTC channel, which undermined the pricing discipline Holley historically had with its resellers and distributors and further damaged Holley’s relationship with its resellers and distributors; (iii) as a result of Holley’s strained relationships with its resellers and distributors, those resellers and distributors were decreasing their purchases of Holley products, returning products already purchased at levels far above historical norms, and increasing their purchases of competitors’ products; (iv) Holley’s growing DTC channel could not offset the negative financial impact of the Company's increasingly strained relationships with its resellers and distributors and, as a result, Holley’s critical relationship with resellers and distributors was deteriorating; (v) Holley had failed to successfully integrate and capture synergies from its numerous acquisitions, which left Holley with inefficient operations, excess costs, and inventory management problems; and (vi) Holly benefited from COVID-related stimulus money that temporarily boosted its sales and performance, and despite this unsustainable, temporary boost, defendants misled investors to believe the growth was sustainable and the result of persistent demand and supportive of positive financial guidance.

Class Period

7/21/21 - 2/6/23

Deadline

January 5 2024

Learn More

31

Days Left

LICY

Li-Cycle Holdings Corp.

Deadline

January 8 2024

Class Period

6/14/22 - 10/23/23

Allegations

(1) the Company’s facility in Rochester, New York (the “Rochester Hub”) was experiencing escalating construction costs; (2) these “escalating construction costs” exceeded the expected aggregate cost of the project; (3) as a result, the Company would be forced to temporarily halt construction and reevaluate the construction strategy for the Rochester Hub; and (4) as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Class Period

6/14/22 - 10/23/23

Deadline

January 8 2024

Learn More

31

Days Left

FMC

FMC Corporation

Deadline

January 8 2024

Class Period

2/9/22 - 10/30/23

Allegations

(1) the diminishment of patent protection for FMC’s flagship products following legal defeats in key markets including India, China, and Brazil had opened the door to increased competition from generics; (2) the Company repeatedly mislead investors about the status of such proceedings and falsely claimed that it did not and would not face generic competition in key markets until 2026 at the earliest; and (3) because of these issues, defendant’s positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Class Period

2/9/22 - 10/30/23

Deadline

January 8 2024

Learn More

32

Days Left

ILMN

Illumina, Inc.

Deadline

January 9 2024

Class Period

5/1/23 - 10/16/23

Allegations

(1) certain of the Company’s insiders had personal financial motives for acquiring GRAIL, Inc.; (2) contrary to Illumina’s attempts to discount Icahn’s criticism, Icahn had accurately concluded that insiders’ interests did not align with the Company’s best interests; and (3) as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Class Period

5/1/23 - 10/16/23

Deadline

January 9 2024

Learn More

32

Days Left

PAYC

Paycom Software, Inc.

Deadline

January 9 2024

Class Period

5/3/23 - 11/1/23

Allegations

(1) Paycom’s Beti product led to cannibalization of the Company’s services and revenues; (2) Paycom knew but failed to disclose that Beti was leading to cannibalization of the Company’s services and revenues, and failed to warn of cannibalization as a general risk; (3) as a result of cannibalization of revenue, Paycom missed its expected 3Q23 revenue and would have to revise its expected 2023 Revenues; (3) the cannibalization issue resulted in projected 2024 year-over-year revenue growth to between 10% and 12%, well below expectations; and (5) as a result, defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Class Period

5/3/23 - 11/1/23

Deadline

January 9 2024

Learn More

35

Days Left

JRVR

James River Group Holdings, Ltd.

Deadline

January 12 2024

Class Period

8/7/23 - 11/7/23

Allegations

(1) James River lacked effective internal controls regarding the recognition of reinstatement premiums for reinsurance; (2) as a result, the Company overstated its net income; (3) the Company was reasonably likely to restate its financial results; and (4) as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Class Period

8/7/23 - 11/7/23

Deadline

January 12 2024

Learn More

39

Days Left

SMR

NuScale Power Corporation

Deadline

January 16 2024

Class Period

3/15/23 - 11/8/23

Allegations

(1) because of the effect of inflationary pressures on the cost of construction and power, the Company and Utah Associated Municipal Power Systems would be unable to sign up enough subscribers to fulfill the Carbon Free Power Project; (2) Standard Power did not have the financial ability to support its agreement with NuScale; and (3) as a result, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Class Period

3/15/23 - 11/8/23

Deadline

January 16 2024

Learn More

39

Days Left

SKIN

The Beauty Health Company

Deadline

January 16 2024

Class Period

5/10/22 - 11/13/23

Allegations

(1) Syndeo 1.0 and 2.0 devices had issues leading to “frequent treatment interruptions;” (2) as a result, the Company incurred significant costs to develop enhancements; (3) despite the enhancements, providers continued to experience issues with the Syndeo devices; (4) as a result, the Company would no longer market Syndeo 1.0 and 2.0 devices and incur significant inventory write-downs; (5) as a result, the Company’s profitability would be adversely impacted; and (6) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Class Period

5/10/22 - 11/13/23

Deadline

January 16 2024

Learn More

39

Days Left

SLRN

Acelyrin, Inc.

Deadline

January 16 2024

Class Period

5/4/23 - 9/11/23

Allegations

(i) izokibep, the Company's lead product candidate, was less effective in treating Hidradenitis Suppurativa than defendants had led investors to believe; (ii) accordingly, Acelyrin overstated izokibep’s clinical and/or commercial prospects; (iii) as a result, Acelyrin also overstated the Company’s business prospects post-initial public offering; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.

Class Period

5/4/23 - 9/11/23

Deadline

January 16 2024

Learn More

39

Days Left

SKIN

The Beauty Health Company

Deadline

January 16 2024

Class Period

5/10/22 - 11/13/23

Allegations

(1) Syndeo 1.0 and 2.0 devices had issues leading to “frequent treatment interruptions;” (2) as a result, the Company incurred significant costs to develop enhancements; (3) despite the enhancements, providers continued to experience issues with the Syndeo devices; (4) as a result, the Company would no longer market Syndeo 1.0 and 2.0 devices and incur significant inventory write-downs; (5) as a result, the Company’s profitability would be adversely impacted; and (6) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Class Period

5/10/22 - 11/13/23

Deadline

January 16 2024

Learn More

45

Days Left

GNRC

Generac Holdings, Inc.

Deadline

January 22 2024

Class Period

5/3/23 - 8/3/23

Allegations

The complaint alleges that on August 2, 2023, the Company held its Q2 2023 earnings call. During that call, President and CEO Aaron P. Jagfeld revealed lackluster quarterly results, including a $1 billion sales decrease year-over-year and that residential sales decreased 44%. When explaining that decline, Jagfeld contradicted his May statements discounting macroeconomic trends. He said, “[the Company] underperformed our expectations as a result of the shift in consumer spending patterns,” thus admitting the importance of inflation on consumer spending. Consequently, Jagfeld advised investors, “[t]his weaker than previously expected demand environment is expected to persist in the second half of the year, also contributing to our lower outlooked for residential product sales.” Generac’s share price dropped swiftly in the day after the earnings call. On August 1, 2023 shares closed to $153.38; by the close on August 3, 2023 shares plummeted to $110.77.

Class Period

5/3/23 - 8/3/23

Deadline

January 22 2024

Learn More

45

Days Left

MDRX

Veradigm Inc.

Deadline

January 22 2024

Class Period

2/26/21 - 6/13/23

Allegations

(a) Veradigm had overstated its historical revenues by at least $20 million; (b) Veradigm had artificially inflated its revenue by recording duplicate transactions, among other things, over a more than two-year period; (c) Veradigm had artificially inflated its earnings and margins and materially misrepresented demand for the Company’s products and services during the class period; (d) Veradigm had failed to maintain effective internal controls over its financial reporting; (e) Veradigm had failed to comply with Generally Accepted Accounting Principles (“GAAP”) regarding appropriate revenue recognition practices; and (f) as a result of the foregoing, the Company’s financial projections were materially false and misleading and lacked any reasonable basis.

Class Period

2/26/21 - 6/13/23

Deadline

January 22 2024

Learn More

49

Days Left

DG

Dollar General Corporation

Deadline

January 26 2024

Class Period

This lawsuit is on behalf of all purchasers of Dollar General common stock between May 28, 2020 and August 30, 2023, inclusive.

Allegations

(a) Dollar General stores were chronically understaffed and suffering from logistical and inventory management problems that left stores with tens of millions of dollars’ worth of outdated and unwanted inventory, mispriced goods, and lost and damaged items; (b) large backlogs of unsellable merchandise had built up at Dollar General’s stores, which inventory had not been timely written down due to understaffing and the Company’s failure to manage its inventory; (c) the allotment of employee hours per store per week imposed by Dollar General management placed employees in virtually impossible situations where assigned tasks, including those necessary for effective store operations, could not be completed within the allotted time; (d) in violation of state laws, including state law violations identified by state regulators in Arizona, Louisiana, Mississippi, Missouri, North Carolina, and Ohio, Dollar General was systematically overcharging customers for items upon checkout; (e) Dollar General’s reported revenue and earnings during the class period were artificially inflated by defendants’ over-pricing scheme; (f) Dollar General’s failure to manage store inventories and accurately price items upon checkout risked the loss of customers, lower sales, adverse regulatory actions, and reputational fallout; (g) Dollar General was not on track to achieve the 4Q22 guidance provided to investors of 6% to 7% same-store sales growth or quarterly diluted EPS of $3.15 to $3.30 and was running more than one hundred million dollars behind the Company’s annual net sales guidance of 11% growth; and (h) as a result of (a)-(g) above, defendants’ statements about Dollar General’s business metrics, operations, and financial prospects were materially false and misleading and/or lacked a reasonable factual basis when made.

Class Period

This lawsuit is on behalf of all purchasers of Dollar General common stock between May 28, 2020 and August 30, 2023, inclusive.

Deadline

January 26 2024

Learn More

49

Days Left

RBLX

Roblox Corporation

Deadline

January 26 2024

Class Period

3/10/21 - 2/15/22

Allegations

(1) the Roblox platform had insufficient content controls and lacked user spending restrictions; (2) these inadequate controls enabled younger Roblox users to play games with inappropriate content and make excessive, unauthorized Robux purchases; (3) a material portion of Roblox’s bookings and revenue growth was due to these excessive, unauthorized Robux purchases; (4) fourth quarter 2021 and 2022 bookings would be negatively impacted by Roblox’s planned rollout of enhanced parental controls; and (5) based on the foregoing, the Company’s bookings and revenue growth was unsustainable throughout the class period.

Class Period

3/10/21 - 2/15/22

Deadline

January 26 2024

Learn More

49

Days Left

FSR

Fisker Inc.

Deadline

January 26 2024

Class Period

8/4/23 - 11/20/23

Allegations

(1) Fisker had a material weakness in its internal control over financial reporting; (2) Fisker had incorrectly accounted for certain costs; (3) as a result, the Company was likely to delay filing its quarterly report; (4) Fisker’s infrastructure was limiting its ability to deliver its production; and (5) as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Class Period

8/4/23 - 11/20/23

Deadline

January 26 2024

Learn More

52

Days Left

CHPT

ChargePoint Holdings, Inc.

Deadline

January 29 2024

Class Period

6/1/23 - 11/16/23

Allegations

(1) the Company was experiencing higher component costs and supply overruns for first-generation DC charging products; (2) as a result, the Company was likely to incur impairment charges; (3) as a result of the foregoing, the Company’s profitability would be adversely impacted; and (4) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Class Period

6/1/23 - 11/16/23

Deadline

January 29 2024

Learn More

52

Days Left

EXFY

Expensify, Inc.

Deadline

January 29 2024

Class Period

This lawsuit is on behalf of all those who purchased or otherwise acquired Expensify common stock pursuant and/or traceable to the registration statement and related prospectus issued in connection with the Company’s initial public offering conducted on or about November 11, 2021.

Allegations

According to the complaint, the offering documents issued by the Company in connection with its initial public offering (the "Offering Documents") made false and/or misleading statements and/or failed to disclose that: (i) Expensify’s revenue growth was highly susceptible to structural and macroeconomic headwinds; (ii) as a result, the Company overstated the efficacy of its business model and the likelihood it would meet the long-term growth projections touted in the Offering Documents; (iii) accordingly, the Company’s post-IPO financial position and/or business prospects were overstated; and (iv) as a result, defendants’ statements about the Company’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Class Period

This lawsuit is on behalf of all those who purchased or otherwise acquired Expensify common stock pursuant and/or traceable to the registration statement and related prospectus issued in connection with the Company’s initial public offering conducted on or about November 11, 2021.

Deadline

January 29 2024

Learn More

53

Days Left

LPSN

LivePerson, Inc.

Deadline

January 30 2024

Class Period

5/10/22 - 3/16/23

Allegations

(i) the Company’s disclosure controls and procedures contained a material weakness; (ii) accordingly, LivePerson maintained deficient internal controls over its financial reporting; (iii) as a result, LivePerson’s Q3 2022 financial statements failed to disclose the suspension of its acquisition WildHealth’s Medicare reimbursements in connection with the Program and the resulting negative impact on the Company’s future revenues; (iv) accordingly, LivePerson had overstated the Company’s future financial position and/or prospects; and (v) as a result, the Company’s public statements were materially false and misleading at all relevant times.

Class Period

5/10/22 - 3/16/23

Deadline

January 30 2024

Learn More

56

Days Left

EH

EHang Holdings Limited

Deadline

February 2 2024

Class Period

1/20/22 - 11/6/23

Allegations

(1) EHang had continued to state that it was partnering with United Therapeutics, DHL and Vodafone, among others, even though a former EHang employee has noted that United Therapeutics, DHL, and Vodafone had all abandoned their respective deals with EHang; (2) EHang omitted that other entities that had placed pre-orders for its aircraft, such as Prestige Aviation and Shenzhen Boling Holding Group, did not engage in regular business in the aviation sector and are otherwise almost certainly not in a financial position to be able to afford their orders; and (3) as a result, defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Class Period

1/20/22 - 11/6/23

Deadline

February 2 2024

Learn More

59

Days Left

EL

The Estee Lauder Companies, Inc.

Deadline

February 5 2024

Class Period

8/18/22 - 5/2/23

Allegations

According to the complaint, defendants misled investors with unrealistic and materially false statements about market demand Estee’s products and its inventory levels. These statements concealed the truth about Estee’s weakness in the market until, on May 3, 2023, Estee announced weaker sales and profit for the year than estimated and accordingly cut its fiscal year outlook for a third consecutive time. As a result, the price of Estee stock declined from $245.22 per share on May 2, 2023 to $202.70 per share on May 3, 2023.

Class Period

8/18/22 - 5/2/23

Deadline

February 5 2024

Learn More

59

Days Left

MVST

Microvast Holdings, Inc.

Deadline

February 5 2024

Class Period

10/19/22 - 11/20/23

Allegations

(1) there was a reasonable likelihood that, after due diligence was performed, Microvast would not be awarded the proposed $200 million grant from the United States Department of Energy; (2) negotiations had ceased and the grant rescinded; (3) the Company misrepresented the nature and profitability of its businesses and partnerships; and (4) as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Class Period

10/19/22 - 11/20/23

Deadline

February 5 2024

Learn More

View All Deadlines

News

Stay informed with the latest in settlement notices, case updates, publications, analyst reports, and more.
View All News

Learn More

Judge Appoints Co-Lead Counsel in Case Against Tandem Diabetes Care, Inc.
On December 5, 2023, Marilyn L. Huff, Senior District Judge in the United States District Court for the Southern District of California, signed an order appointing a group of plaintiffs, Mason Raines, Thomas O. Martel, and Linna Rae Martel, as Co-Lead Plaintiffs in the securities fraud case captioned Lowe V. Tandem Diabetes Care, Inc. et al.,...Read more

December 7, 2023

Learn More

L&K Appointed Lead Counsel in Rain Oncology Lawsuit
On November 1, 2023, The United States District Court for the Northern District of California appointed Levi & Korsinsky as Lead Counsel in the pending class action lawsuit, Thant V. Rain Oncology Inc. et al., 5:23-cv-03518-EJD. We look forward to using our firm’s extensive class action and securities litigation experience to pursue recovery for shareholders. Review the...Read more

November 2, 2023

Learn More

Proof of Claim Deadline Approaching for The GEO Group, Inc. Settlement
On May 8, 2023, following extensive mediation, The GEO Group, Inc. and aggrieved investors reached a settlement of $3 million in the securities fraud lawsuit pending in the District Court for the Southern District of Florida (Hartel v. The GEO Group, Inc. et al., Case No. 9:20-cv-81063). This settlement received preliminary approval by the court...Read more

November 1, 2023

View All News

Our World-Class Team

Levi & Korsinsky’s attorneys are admitted in over 40 state, federal, and appeal courts across the country. We have the specialized securities skills to achieve outstanding results, and our impressive variety of backgrounds means that we can go up against large companies of any kind and win. Our powerhouse attorneys have backgrounds in accounting, engineering, SEC enforcement, mathematics, regulatory analysis, international business, and prosecution, to name just a few. . .

View Attorneys